About Aurore Life Sciences
Aurore Life Sciences is a Healthcare company based in Hyderabad (India). It develops and produces Active Pharmaceutical Ingredients and intermediates for pharmaceutical markets. It operates on a B2B and Manufacturing Supply model. Aurore Life Sciences has raised $5.12 million across 2 funding rounds. The company has 338 employees. Its Indian entity Aurore Life Sciences Private Limited reported revenue of ₹471 Cr. Aurore Life Sciences offers products and services including Verapamil, Valacyclovir, Levothyroxine Sodium, Dronaderone, and Raltegravir. Its focus areas include Pharmaceuticals, API Manufacturing, Drug Intermediates and Active Ingredients. Its competitors include Laurus Labs, Symbiotec and SeQuent; 2 of its 3 listed competitors have raised funding.
Company details
Aurore Life Sciences focuses on developing and manufacturing Active Pharmaceutical Ingredients (APIs) and intermediates through advanced RD and compliant processes. They operate FDA-approved facilities with expertise in innovation and global standards. Based in Hyderabad, India, they serve international clients by providing reliable, scalable production for various therapeutic areas including anti-arrhythmics and antivirals.
- Headquarters Hyderabad, India
- Employees 338
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website aurorels.com
- Legal Name Aurore Life Sciences Private Limited
- Date of Incorporation 26 Sep, 2016
- Jurisdiction Mumbai, Maharashtra, India
- Annual Revenue₹471 Cr
FY 2025 · +5% YoY
- Net Loss-₹34.02 Cr
FY 2025 · -7% margin
- EBITDA₹55.50 Cr
FY 2025 · 12% margin
- Total Equity Funding$5.12M (USD)
in 2 rounds
- Latest Funding Round$17.35K (USD), Series A
Mar 2019
- Employee Count338
Associated legal entities of Aurore Life Sciences
Aurore Life Sciences is associated with 4 registered companies on The Company Check; the primary company is Aurore Life Sciences Private Limited. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Aurore Life Sciences Private Limited CIN U74999MH2016PTC371990 | Active | 26 Sep 2016 | Mumbai, Maharashtra | ₹471 Cr | 437 | 5 | View details |
| Aurore Pharmaceuticals Private Limited CIN U24239TG2017PTC117032 | Active | 15 May 2017 | Hyderabad, Telangana | ₹94.5 Cr | 451 | 4 | View details |
| Hydra Active Pharma Sciences Private Limited CIN U74999MH2016PTC365641 | Active | 06 Dec 2016 | Mumbai, Maharashtra, India | View details | |||
| Hydra Active Pharma Sciences Private Limited CIN U74999KA2016PTC197435 | Active | 06 Dec 2016 | Bangalore, Karnataka | ₹2.0 Cr | 2 | View details |
Products & Services of Aurore Life Sciences
Aurore Life Sciences offers a comprehensive portfolio of products and services, including Verapamil, Valacyclovir, Levothyroxine Sodium, Dronaderone, and Raltegravir.
Medication for treating heart rhythm disorders with global filings.
Drug for viral infections like herpes with various regulatory approvals.
Treatment for hypothyroidism with international certifications.
Medication for arrhythmia management in healthcare applications.
Antiretroviral drug for HIV treatment purposes.
Drug for epilepsy control with production capacities.
Treatment for irregular heartbeats in patients.
Medication for inflammation-related conditions globally.
Antiviral treatment for infections like herpes simplex.
Stabilizer for transthyretin in amyloidosis therapy.
Anti-inflammatory drug for pain and swelling relief.
Hormone replacement for thyroid conditions.
Blood thinner for preventing clots effectively.
Allergy relief medication with regulatory approvals.
Funding Insights of Aurore Life Sciences
Aurore Life Sciences has successfully raised a total of $5.12M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $17.35 thousand completed in March 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5.12M
- Total Rounds 2
- Last Round Series A — $17,347
- First Round $5.1M
(Jun 2018)
All 2 funding rounds of Aurore Life Sciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2019 | $17,347 | Series A | – | – | – |
| Jun 2018 | $5.1M | Series A | – | – | – |
Board of directors of Aurore Life Sciences Private Limited (Aurore Life Sciences)
Aurore Life Sciences Private Limited is the primary company behind Aurore Life Sciences. The boards of the 3 registered companies of Aurore Life Sciences currently have 8 directors; the longest-serving is Ramaprasad Jyothinagaravyasha Sriraman, appointed in 2016. 28 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Ramaprasad Jyothinagaravyasha Sriraman DIN 00173696 | Director | 06 Dec 2016 | 9 yrs 10 mo | Hydra Active Pharma Sciences Private Limited |
| Rajender Juvvadi Rao DIN 00083540 | Managing Director | 15 Jun 2017 | 9 yrs 4 mo | Aurore Life Sciences Private Limited |
| Chandrappa Seetharamaiah DIN 07405773 | Director | 31 Dec 2020 | 5 yrs 9 mo | Hydra Active Pharma Sciences Private Limited |
| Sareddy Reddy Ravisankara DIN 07994163 | Nominee Director | 06 Dec 2022 | 3 yrs 10 mo | Aurore Pharmaceuticals Private Limited |
| Sailesh Jhawar Kumar DIN 08069363 | Director | 18 Sep 2024 | 2 yrs 1 mo | Aurore Pharmaceuticals Private Limited |
| Pudhucode Radhakrishnan Kannan DIN 03435209 | Additional Director | 13 Jan 2025 | 1 yr 9 mo | Aurore Life Sciences Private Limited |
| Dilip Murthy Buddha DIN 11100973 | Nominee Director | 01 Oct 2025 | 1 yr | Aurore Life Sciences Private Limited |
| Suresh Mudhunuri DIN 08077539 | Nominee Director | 01 Oct 2025 | 1 yr | Aurore Life Sciences Private Limited |
People of Aurore Life Sciences
4 people are tracked at Aurore Life Sciences (3 in leadership, 1 in team); the tracked headcount is 338.
| Name | Role | Group |
|---|---|---|
Revanth Kothoju | Head - Strategic Business Development (avp) | Leadership |
Bhaskar Reddy | Assistant General Manager - Business Development | Leadership |
| Founder | Leadership | |
Deepti Pathak | People & Culture Advisor | Team |
Complete people profiles for Aurore Life Sciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Aurore Life Sciences
Figures of Aurore Life Sciences Private Limited, the primary company behind Aurore Life Sciences, for FY 2025. Revenue was ₹471 Cr (+5% year on year). Net loss was -₹34.02 Cr (-7% margin). EBITDA was ₹55.50 Cr (12% margin). Revenue has grown at a compounded annual rate of +2% over three years and +18% over five years.
- ₹471 CrRevenue · FY 2025 · +5% YoY
- -₹34.02 CrNet loss · -7% margin
- ₹55.50 CrEBITDA · 12% margin
- ₹117 CrPaid-up capital
- 437Employees (provident fund records)
- +2%Revenue CAGR, 3 years
- +18%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Aurore Life Sciences Private Limited are on its company page.
Detailed financial statements for Aurore Life Sciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Aurore Life Sciences
2 dated milestones of Aurore Life Sciences across 1 years, from founding to its latest funding, stage changes and deals.
- Funding First funding round of $5.1M.
- Funding Latest funding round, Series A, of $17K.
Competitors of Aurore Life Sciences
Aurore Life Sciences has 3 listed competitors in our database, 2 of them funded. They include Laurus Labs, Symbiotec and SeQuent.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| lauruslabs.com | 2005 | Hyderabad, India | $229.73M | 6,035 | Pharmaceutical and biotechnology company | |
| symbiotec.in | 2002 | Indore, India | $61.01M | 1,822 | Non-sterile steroid hormone-based APIs and intermediates are manufactured. | |
| sequent.in | 2002 | Bengaluru, India | APIs are developed and manufactured for therapeutic areas. |
Detailed competitors of Aurore Life Sciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Aurore Life Sciences
The website of Aurore Life Sciences (aurorels.com) receives about 1.3K visits a month.
- Monthly visits1.3K
▼ 11.5% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aurore Life Sciences
Complete news archive for Aurore Life Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aurore Life Sciences
Aurore Life Sciences is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Aurore Life Sciences is a funded company, having raised a total of $5.12M across 2 funding rounds to date. The company's 1st funding round was a Series A of $5.1M, raised on Jun 2018.
Aurore Life Sciences has 338 employees.
The primary company behind Aurore Life Sciences, Aurore Life Sciences Private Limited, reported revenue of ₹471 Cr for FY 2025, up 5% year on year.
Aurore Life Sciences focuses on developing and manufacturing Active Pharmaceutical Ingredients (APIs) and intermediates through advanced RD and compliant processes. They operate FDA-approved facilities with expertise in innovation and global standards. Based in Hyderabad, India, they serve international clients by providing reliable, scalable production for various therapeutic areas including anti-arrhythmics and antivirals.
Aurore Life Sciences's top competitors include Laurus Labs, Symbiotec and SeQuent.
Aurore Life Sciences offers Verapamil, Valacyclovir, Levothyroxine Sodium, Dronaderone, and 6 more products and services.
Aurore Life Sciences is associated with 3 legal entities: Aurore Life Sciences Private Limited, Hydra Active Pharma Sciences Private Limited, Aurore Pharmaceuticals Private Limited.
The legal entities of Aurore Life Sciences currently have 10 directors, including Ramaprasad Jyothinagaravyasha Sriraman, Chandrappa Seetharamaiah, Vamsilatha Thulasi and others.